Neurocrine Biosciences (FRA:NB3) Non Operating Income: € Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NB3 Neurocrine Biosciences Inc FRA:NB3
95 GF Score
Price €126.55
GF Value €171.63
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Neurocrine Biosciences Non Operating Income?

Neurocrine Biosciences FRA:NB3 +1.51% 95 Non Operating Income is € Mil as of Jun. 2026. GuruFocus rates FRA:NB3 with a GF Score™ of 95/100 and a GF Value™ of €171.63 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Neurocrine Biosciences's Non Operating Income for the three months ended in Jun. 2026 was € Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was € Mil.

Neurocrine Biosciences Non Operating Income Related Terms

Neurocrine Biosciences Non Operating Income Historical Data

* Premium members only.

The historical data trend for Neurocrine Biosciences's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences Non Operating Income Chart

Neurocrine Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Neurocrine Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
FRA:NB3
95GF Score
Neurocrine Biosciences Inc FRA:NB3
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurocrine Biosciences Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was € Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of € Mil mean?
Neurocrine Biosciences (FRA:NB3) has a Non Operating Income of € Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Neurocrine Biosciences and its competitors.
Is Neurocrine Biosciences' Non Operating Income too high?
Neurocrine Biosciences' current Non Operating Income is € Mil. Overall, Neurocrine Biosciences has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Non Operating Income compare to VTRS and ELAN?
Neurocrine Biosciences' Non Operating Income of € Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Drug Manufacturers company?
A good Non Operating Income depends on the Drug Manufacturers industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Neurocrine Biosciences and its competitors. Neurocrine Biosciences's current Non Operating Income is € Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Modestly Undervalued. The stock's GF Value™ is €171.63, compared to a current price of €126.55 — trading 26.3% below its estimated fair value. The current Non Operating Income is € Mil. Neurocrine Biosciences' overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current Non Operating Income is € Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of €126.55 is trading 26.3% below its estimated GF Value™ of €171.63. GuruFocus considers Neurocrine Biosciences to be Modestly Undervalued.

Key valuation signals for FRA:NB3:

  • Non Operating Income: € Mil
  • GF Value™: €171.63 vs. price of €126.55 (26.3% below fair value)
  • GF Score™: 95/100 with 3 warning signs

No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
95GF Score

Get the complete analysis for FRA:NB3

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€126.55
Price
€171.63
GF Value